SINOVAC Board Issues Letter to Shareholders to Set the Record Straight on the Hostile Actions and False Claims by Vivo Capital

Contributed by: Business Wire

Tags

Health

Infectious Diseases

COVID-19

Clinical Trials

Pharmaceutical

Biotechnology

Letter to Shareholders Vivo Capital

More Like This

SINOVAC Announces Decision to Declare Cash Dividend

SINOVAC Announces New Board Pursuant to Privy Council Judgment and Order

Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer

SINOVAC Announces Record and Distribution Dates for Special Cash Dividend

SINOVAC Issues Statement Regarding Privy Council Judgment

Heng Ren Partners Demands Sinovac Distribute $8.9 Billion in Cash to its Shareholders and Cause Reinstatement of Trading

Heng Ren Partners Calls on Sinovac to Disclose the Record and Payment Dates of the Special Dividend and Distribute an Additional Dividend of $41 per Share

Sinovac Amends Shareholder Rights Plan